Amedisys (NASDAQ:AMED) Receives Equal Weight Rating from Stephens

Amedisys (NASDAQ:AMED)‘s stock had its “equal weight” rating restated by Stephens in a note issued to investors on Tuesday,Benzinga reports. They currently have a $101.00 price target on the health services provider’s stock. Stephens’ target price points to a potential upside of 9.78% from the stock’s previous close.

Amedisys Price Performance

Shares of AMED opened at $92.00 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a 50 day moving average price of $91.55 and a 200-day moving average price of $93.10. Amedisys has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The stock has a market capitalization of $3.01 billion, a PE ratio of 36.51, a PEG ratio of 1.78 and a beta of 0.73.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The company had revenue of $598.05 million for the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Equities analysts predict that Amedisys will post 4.4 earnings per share for the current fiscal year.

Institutional Trading of Amedisys

Several hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new position in shares of Amedisys during the 4th quarter worth approximately $1,869,000. Vise Technologies Inc. purchased a new position in Amedisys in the fourth quarter worth $248,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Amedisys by 11.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 101,752 shares of the health services provider’s stock worth $9,238,000 after purchasing an additional 10,105 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Amedisys by 2.3% during the 4th quarter. Squarepoint Ops LLC now owns 186,379 shares of the health services provider’s stock valued at $16,921,000 after purchasing an additional 4,158 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of Amedisys by 151.9% in the 4th quarter. Two Sigma Advisers LP now owns 13,600 shares of the health services provider’s stock worth $1,235,000 after purchasing an additional 8,200 shares in the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.